Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Development of UROGRAFT: A Bladder Acellular Matrix-Based Composite for Advanced Cystoplasty, Highlighting the Role of Graft Shape and Composition.

Pokrywczynska M., Fekner Z., Balcerczyk D., Kloskowski T., Rasmus M., Kasinski D.

Animal Study on Systemic / IV, published in ACS Biomater Sci Eng (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
ACS Biomater Sci Eng (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40667861
PMCID
PMC12344642
DOI
10.1021/acsbiomaterials.5c00700

Abstract (original English)

Urinary bladder augmentation with gastrointestinal segments, despite many complications, remains a gold standard treatment of low-capacity, poorly compliant, or refractory overactive urinary bladder. In this study, we developed the UROGRAFT, a new bladder acellular matrix-collagen-cellulose (BAM-CC) composite for urinary bladder augmentation. The study presents the step-by-step development process of UROGRAFT, including the selection of an optimal decellularization protocol and cross-linking method to ensure optimal biomaterial properties. Histological and biochemical analyses demonstrated that the combined protocol of Triton X-100 and sodium dodecyl sulfate (SDS) was the most effective, completely removing cellular components while preserving the extracellular matrix (ECM). DNA quantification confirmed a significant reduction in residual genetic material, ensuring a low immunogenic profile. Scanning electron microscopy (SEM) confirmed high porosity and well-preserved collagen fibers. To reduce porosity and permeability, BAM was cross-linked with collagen type I and dialdehyde carboxymethyl cellulose, optimizing scaffold performance. Biocompatibility tests confirmed the absence of toxicity, tissue reactions, acute systemic toxicity, and mutagenic effects. Based on computational modeling, verified by implantation trials, a unique three-armed graft shape resembling lily petals wa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Urinary BladderAnimalsTissue ScaffoldsCelluloseCollagenSwineBiocompatible MaterialsExtracellular MatrixTissue EngineeringDecellularized Extracellular Matrix

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research